Guégan Mathilde, Bichon Malvina, Chaput Nathalie, Houot Roch, Lemoine Jean
Department of Hematology, CHU de Rennes, Université de Rennes, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.
Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Université Paris-Saclay, Villejuif, Ile-de-France, France.
Eur J Cancer. 2025 Jan;214:115145. doi: 10.1016/j.ejca.2024.115145. Epub 2024 Nov 23.
Cancer immunotherapy, including immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy and bispecific antibodies, has led to major improvements in the treatment of a wide range of hematologic malignancies and solid tumors. However, age-mediated immune system modifications, known as immunosenescence, may preclude its efficacy in elderly patients. In this review, we assessed the efficacy of these different cancer immunotherapies in elderly patients compared to young patients to revisit the concept of immunosenescence from a therapeutic perspective.
癌症免疫疗法，包括免疫检查点抑制剂、嵌合抗原受体T细胞疗法和双特异性抗体，已在多种血液系统恶性肿瘤和实体瘤的治疗中取得了重大进展。然而，年龄介导的免疫系统改变，即免疫衰老，可能会妨碍其在老年患者中的疗效。在本综述中，我们评估了这些不同的癌症免疫疗法在老年患者与年轻患者中的疗效，以便从治疗角度重新审视免疫衰老的概念。
